The Motley Fool Discussion Boards

Previous Page

Stocks A / Ariba, Inc.


Subject:  New business Date:  12/4/2002  7:38 AM
Author:  Donde Number:  3062 of 3069

if we are going to make it the new business needs to rock n' roll..

03 Dec 2002, 10:59 AM EST Msg. 28097 of 28099

SUNNYVALE, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Ariba(R), Inc. (Nasdaq: ARBA), the leading Enterprise Spend Management (ESM) solutions provider, today announced that Yamanouchi Pharmaceutical Co., Ltd. has deployed the Ariba(R) Buyer(TM) procurement solution throughout its Japanese operations. Yamanouchi, the first Japanese-based pharmaceutical company to implement Ariba Buyer in Japan, is using the solution to centralize and streamline its purchasing processes, reduce purchasing costs and cycles and benefit from economies of scale purchasing. Yamanouchi employees have used the solution to electronically purchase a variety of goods and services including lab equipment and supplies, business travel services and office equipment. "Large, multi-national corporations such as Yamanouchi are ideally positioned to reap significant benefits from Enterprise Spend Management, and use it to provide an ongoing competitive edge," said Michael Schmitt, EVP and chief marketing officer, Ariba. "Along with our local partners, Ariba is committed to helping Yamanouchi attain its spend management goals, and to add the company to our growing list of worldwide pharmaceutical success stories for excellence in spend management." In a phased deployment, Yamanouchi commenced the Ariba Buyer rollout in July this year at its head office and Hasune branch in Tokyo, and recently extended the system to 12 domestic branches, four research laboratories, three plants and most of its subsidiaries. The company plans to make new spend commodities, such as contract and temporary labor services, available by the end of 2002. About Yamanouchi Pharmaceutical Co., Ltd. Yamanouchi Pharmaceutical Co., Ltd. (TSE: 4503) is promoting collaboration with other pharmaceutical companies as well as bioventure companies and academia to raise the quality and speed of its R&D activities. Yamanouchi is accelerating new drug discovery research not only with its own R&D capability but also through alliances with a wide range of partners. Yamanouchi's primary objective in R&D is to create a steady stream of innovative new drugs. About Ariba, Inc. Ariba, Inc. is the leading Enterprise Spend Management (ESM) solutions provider. Ariba helps companies develop and leverage spend management as a core competency to drive significant bottom line results. Ariba Spend Management software and services allow companies to align their organizations with a spend-centric focus and deploy closed-loop processes for increased efficiencies and sustainable savings. Ariba can be contacted in the U.S. at 1-650-390-1000 or at NOTE: Ariba and the Ariba logo are registered trademarks of Ariba, Inc. Ariba Spend Management, Ariba Analysis, Ariba Buyer, Ariba Category Management, Ariba Contracts, Ariba Travel & Expense, Ariba Workforce, Ariba Invoice, Ariba eForms, Ariba Enterprise Sourcing, Ariba Supplier Network, BPM Services, Power Sourcing, Total Spend Capture and PO-Flip are trademarks or service marks of Ariba, Inc. Ariba Safe Harbor Safe Harbor Statement Under the Private Securities Litigation Reform Act 1995: Information and announcements in this release involve Ariba's expectations, beliefs, hopes, plans, intentions or strategies regarding the future and are forward-looking statements that involve risks and uncertainties. All forward-looking statements included in this release are based upon information available to Ariba as of the date of the release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to: delays in development or shipment of new versions of Ariba's products and services; lack of market acceptance of Ariba's existing or future products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new pr